Alzamend Neuro, Inc. (ALZN): Cash & Equivalents
$710.7K
As of 2026-04-30
$7.59M
As of 2026-07-31
-48.3%
3-year compound annual growth
-18.1%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2026-04-30 | $710.7K | -82.0% | 2026-07-22, Balance as of period end |
| 2025-04-30 | $3.95M | +950.0% | 2026-07-22, Balance as of period end |
| 2024-04-30 | $376.0K | -92.7% | 2025-07-22, Balance as of period end |
| 2023-04-30 | $5.14M | -63.4% | 2024-07-30, Balance as of period end |
| 2022-04-30 | $14.06M | +629.0% | 2023-07-27, Balance as of period end |
| 2021-04-30 | $1.93M | n/m | 2022-07-19, Balance as of period end |
| 2020-04-30 | $90.3K | n/a | 2021-07-29, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Alzamend Neuro, Inc. (ALZN) | 2026-04-30 | $710.7K | -82.0% |
| Inhibitor Therapeutics, Inc. (INTI) | 2025-12-31 | $2.38M | -57.6% |
| Artelo Biosciences, Inc. (ARTL) | 2025-12-31 | $600.0K | n/a |
| BullFrog AI Holdings, Inc. (BFRG) | 2025-12-31 | $2.18M | -59.8% |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | $58.7K | -9.5% |
| Avenue Therapeutics, Inc. (ATXI) | 2025-12-31 | $2.85M | +10.1% |
| Alaunos Therapeutics, Inc. (TCRT) | 2025-12-31 | $1.39M | +26.9% |
| InMed Pharmaceuticals Inc. (INM) | 2025-06-30 | $11.08M | +68.5% |
| Semnur Pharmaceuticals, Inc. (SMNR) | 2025-12-31 | $20.0K | +66.7% |
Compare ALZN, INTI, ARTL, BFRG side by side · Screen every company in Pharmaceutical Preparations ↗